¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¼ö»óÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ
¸ðüžÆÀÇÇР/   ºÎÀÎÁ¾¾çÇР /   »ý½Ä³»ºÐºñÇР /   ÀϹݺÎÀΰúÇÐ
Æ÷½ºÅÍ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2016³â 9¿ù 23ÀÏ(±Ý) ~ 2016³â 9¿ù 24ÀÏ(Åä)
- Àå¼Ò : EXHIBITION HALL B[1F]
(08:00~17:00)
34-GO0108:00~08:00 ±è¼ö¹Ì
´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú
The induced anti-cancer effects of Radachlorin-mediated photodynamic therapy in human endometrial adenocarcinoma cell line HEC-1-A
35-GO0208:00~08:00 ±è¼ö¹Ì
´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú
Synergistic inhibition of ovarian cancer cell NIH: OVCAR-3 growth by combining a natural isothiocyanate sulforaphene with cisplatin.
36-GO0308:00~08:00 ±èÀºÅÃ
°í½ÅÀÇ´ë º¹À½º´¿ø »êºÎÀΰú
°ñ¹Ý¿¡ ±¹ÇÑµÈ ³­¼Ò¾Ï óġ¿¡¼­ ´ëµ¿¸Æ ÁÖÀ§ °ñ¹Ý ÀÓÆļ± ÀýÀçÀÇ À¯¿ë¼º
37-GO0408:00~08:00 ±èÁö¼·
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
The utility of 2-antibody panel using MSH6 and PMS2 for screening of Lynch syndrome in endometrial cancer patients
38-GO0508:00~08:00 ±èÁøÈÖ
°¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú
Can human papillomavirus testing predict residual/recurrent disease in patients with positive margins after LEEP?
39-GO0608:00~08:00 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Timing and Patterns of Recurrence in Epithelial Ovarian Cancer Patients with No Gross Residual Disease after Primary Debulking Surgery, single institution experience
40-GO0708:00~08:00 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Impact of Lymphadenectomy on Survival after Recurrence in Patients with Advanced Ovarian Cancer without Suspected Lymph Node Metastasis
41-GO0808:00~08:00 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pre-treatment Complete Blood Cell Counts in Epithelial Ovarian Cancer patients
42-GO0908:00~08:00 ¼ºÁß¿±
ÇѸ²ÀÇ´ë ¼º½Éº´¿ø »êºÎÀΰú
Anticancer effect of propranolol in ovarian cancer cells regardless of platinum sensitivity
43-GO1008:00~08:00 ¼ÕÁÖÇõ
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Clinicopathologic factors of ovarian clear cell carcinoma in a background of endometriosis: Clues for proper treatment and follow up intervals
44-GO1108:00~08:00 ¼Û°üÈí
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Risk factor analysis for massive lymphatic ascites after laparoscopic retroperitonal lymphadenectomy in gynecologic cancers and treatment using intranodal lymphangiography with glue embolization
45-GO1208:00~08:00 ½É¹ÎÈñ
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Dynamin 2 inhibitors as novel therapeutic agents in cervical cancer cells
46-GO1308:00~08:00 ¿À¼Ò¶ó
µ¿¾Æ´ëÇб³º´¿ø »êºÎÀΰú
Comparison of four malignancy risk indices in the preoperative evaluation of patients with borderline ovarian tumor
47-GO1408:00~08:00 À±°¡¿µ
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
Autotaxin-lysophosphatidic acid-LPA receptor 1 signaling can be a prominent target for development of therapy of epithelial ovarian cancer
48-GO1508:00~08:00 À±Á¤¿ø
¿¬¼¼ÀÇ´ë »êºÎÀΰú
End-of-Life care for women with ovarian cancer in Korea
49-GO1608:00~08:00 ÀÌ°Ç¿ì
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
The safety and efficacy of bleomycin, etoposide and cisplatin (BEP) chemotherapy in patients with malignant ovarian germ cell tumor
50-GO1708:00~08:00 À̹ÎÈñ
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú
Minimal deviation adenocarcinoma (Adenoma malignum) of the uterine cervix; Clinicopathological analysis of 16 cases
51-GO1808:00~08:00 ÀÌ»óÈÆ
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
A pilot study of HPV genotypes and prevalence in Korean women in the specific district of Seoul
52-GO1908:00~08:00 À̽¹Ì
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Long-term follow-up study of adult-type ovarian granulosa cell tumor
53-GO2008:00~08:00 À̽¹Ì
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Clinical outcome and Adverse effects of Pegylated Liposomal Doxorubicin in Korean patient with Ovarian cancer: the Experiences of single center.
54-GO2108:00~08:00 À̽¹Ì
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Patterns and utility of routine surveillance in stage III-IV endometrial cancer
55-GO2208:00~08:00 ÀÌ¿µÀç
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
The prognostic factors in node-positive cervical cancer patients who underwent radical hysterectomy and pelvic lymph node dissection with or without para-aortic lymph node dissection
56-GO2308:00~08:00 ÀÌ¿µÀç
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Pathologic findings at risk-reducing salpingo-oophorectomy in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers
57-GO2408:00~08:00 ÀÌÀ¯°æ
Predictive value of p16/Ki-67 dual-stained cytology for the progression of cervical dysplasia: HPV cohort study
58-GO2508:00~08:00 ÀÌÀ±°æ
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Outcomes of single port access surgical staging for twenty-one endometrial cancer patients
59-GO2608:00~08:00 ÀÌÁ¤À±
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
External validation of chemotherapy response scoring system for histopathologic assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high grade serous carcinoma
60-GO2708:00~08:00 ÀåÀÍÁø
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
Distribution of HPV genotypes in association with cytological & histological results in Korean women.
61-GO2808:00~08:00 ÀåÇϱÕ
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Prognostic factors in patients with metastatic ovary tumors: multi-center study
62-GO2908:00~08:00 ÀåÇý¸®
ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú
The clinical importance of the para-aortic lymphadenectomy up to the level of the renal vessels in Endometrial cancer and Ovarian cancer
63-GO3008:00~08:00 Àü¼¼Á¤
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
64-GO3108:00~08:00 Àü¼ö¿¬
°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
G-protein-coupled estrogen receptor-30 gene single nucleoid polymorphisms in ovarian cancer
65-GO3208:00~08:00 Á¤´ÙÀº
¿¬¼¼´ëÇб³ ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø »êºÎÀΰú
Overexpression of miR-9, miR-21, miR-155, and miR-944 in Formalin-Fixed Paraffin-Embedded Cervical Cancer Tissues
66-GO3308:00~08:00 Á¤¿¬ÁØ
Áß¾Ó´ëÇб³º´¿ø »êºÎÀΰú
DKK3, downregulated in epithelial invasive ovarian cancer, inhibits proliferation and invasiveness of ovarian cancer cells by regulating MMP-2, MMP-9 and ¥â-catenin
67-GO3408:00~08:00 Á¤¿µ½Å
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Laparoendoscopic Single Site Surgery for Cervical Cancer: A Single Surgeon Experience
68-GO3508:00~08:00 Á¤À±Áö
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Anticancer funtional mechanism of Müllerian inhibiting substance/anti-Müllerian hormone concern with ICAT by regulating Wnt signal pathway in ovarian cancer
69-GO3608:00~08:00 Á¶Çö³ç
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
Pseudocarcinomatous hyperplasia of the Fallopian tube mimicking Tubal cancer: Radiological and Pathological diagnostic challenge
70-GO3708:00~08:00 °øÁø°æ
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Establishment of immortalized human ovarian surface epithelial cells using the lentiviral system from Korea Gynecologic Cancer Bank
71-GO3808:00~08:00 ÃÖµ¿¼®
ÃÖ»ó»êºÎÀΰúÀÇ¿ø
Symptom score change and volume reduction of uterine fibroid and adenomyosis after treatment with ultrasound guided high intensity focused ultrasound
72-GO3908:00~08:00 ÃÖÀ±Áø
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
E2/E6 ratio and L1 immunoreactivity as markers for detecting HPV16 positive > CIN2 lesions and cervical squamous cell carcinomas
73-GO4008:00~08:00 ÃÖÇöÁø
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Development of orthotopic Patient-derived tumor xenograft models in endometrial cancer
74-GO4108:00~08:00 Çѳª¿µ
¼­¿ï´ëÇб³º´¿ø º´¸®°ú
Àå¾×¼º ³­¼Ò¾Ï¿¡¼­ÀÇ CD47 ¹ßÇö
75-GO4208:00~08:00 ÇѽÃÀº
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
FOXP1: valuable target for development of treatment of cancer stem cells in ovarian cancer.
76-GO4308:00~08:00 È«ÁøÈ­
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
Prognostic value of the sum of metabolic tumor volume of primary tumor and lymph nodes using 18F-FDG PET/CT in patients with cervical cancer
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2016³â 9¿ù 23ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F]
GO01-GO05 (08:20~09:10) ÁÂÀå : ±è¿ë¹ü(¼­¿ïÀÇ´ë)
GO0108:20~08:30 ±âÀº¿µ
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Immunocytochemistry negativity for human papillomavirus L1 capsid protein as a biomarker in atypical squamous cell of undetermined significance or low grade squamous intraepthelial lesion
GO0208:30~08:40 È«¿µÈñ
°Ç±¹´ëÇб³º´¿ø »êºÎÀΰú
Impact of Adjuvant Hysterectomy on Prognosis in Patients with Locally Advanced Cervical Cancer Treated with Definitive Chemoradiation: A Meta-Analysis
GO0308:40~08:50 °­¼º¿ì
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: a propensity score matching study
GO0408:50~09:00 ÀÌÀοÁ
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Uniformed Indocynine Green injection protocol; the effective factor of increasing optimal sentinel lymph node mapping rate in cervical and endometrial cancers
GO0509:00~09:10 ÀÌÁöÇý
°Ç±¹´ëÇб³º´¿ø »êºÎÀΰú
Prediction model for para-aortic lymph node metastasis in patients with locally advanced cervical cancer
GO06-GO10 (09:10~10:00) ÁÂÀå : ±è¿µÅ¹(¿ï»êÀÇ´ë)
GO0609:10~09:20 ¾î°æÁø
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Germline Mutations in Patients with Epithelial Ovarian Cancer using Gene-Panel Sequencing: Beyond BRCA 1/2
GO0709:20~09:30 À̽ÅÈ­
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Potential urinary biomarker panel to predict malignancy in women with pelvic masses
GO0809:30~09:40 ±Ç¿ëÀÏ
À¯·ÎÁø»êºÎÀΰú
Glycan Markers for Ovarian Cancer with High Sensitivity and High Specificity
GO0909:40~09:50 ÀÌÁ¤¿ø
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Anti-cancer Effect of Ulipristal Acetate in Uterine Leiomyosarcoma
GO1009:50~10:00 À̽¹Ì
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Development of a female animal model for anatomical and functional assessment of the pelvic autonomic nerves in women
GO11-GO15 (10:30~11:20) ÁÂÀå : Çã¼ö¿µ(°¡Å縯ÀÇ´ë)
GO1110:30~10:40 ±èÈñÁ¤
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Long non-coding RNA HOXA11 antisense promotes tumor progression and predicts patient prognosis in serous ovarian cancer
GO1210:40~10:50 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
The Effect of Chemical inhibition of Lysyl-tRNA Synthase-Laminin Receptor in Ovarian Cancer
GO1310:50~11:00 À±Á¤¼ö
°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
The long non-coding RNAs in the epithelial recurrent ovarian cancer
GO1411:00~11:10 ±èÈñÁ¤
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Steroid Receptor Activator modulates proliferation and invasion in the human cervical cancer
GO1511:10~11:20 ¼­µ¿¼ö
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
Selective cytotoxic effect of non-thermal micro-DBD plasma in uterine cervical cancer cells
GO16-GO20 (11:20~12:10) ÁÂÀå : ÀÌÀ±¼ø(°æºÏÀÇ´ë)
GO1611:20~11:30 ¾î°æÁø
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Long Term Survival Analysis of Carboplatin or Cisplatin Based Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
GO1711:30~11:40 À±¹ÎÁ¤
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Dose-dense paclitaxel and carboplatin for ovarian carcinoma among Korean population: single institution experience
GO1811:40~11:50 ±è¹Ì¼±
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Survival impact of low anterior resection in the patients with epithelial ovarian cancer grossly confined to pelvic cavity: A multicenter retrospective study
GO1911:50~12:00 °ûÀ翵
¿ï»ê´ëÇб³º´¿ø »êºÎÀΰú
Adjuvant treatment strategy of pathological down-staged patients after radical surgery of locally advanced cervical cancer with neoadjuvant chemotherapy
GO2012:00~12:10 ¿ÀÁøÁÖ
´ë±¸°¡Å縯´ëÇб³º´¿ø »êºÎÀΰú
The cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance
GO21-GO24 (12:10~12:50) ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë)
GO2112:10~12:20 ±Ç¹ÎÁ¤
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Rapid genetic screening experience among endometrial cancer about Lynch syndrome by surgeon
GO2212:20~12:30 À¯Áö±Ù
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Prevalence and outcome of BRCA mutation in Korean epithelial ovarian cancer women
GO2312:30~12:40 ÀÓ¿µ¹Ì
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú
Hypermethylation of the Single-minded homolog 1 (SIM1) as a novel biomarker for cervical cancer screening
GO2412:40~12:50 ÀåűÔ
°è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú
Natural course of HPV positive women in Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion and association of HPV genotype : HPV cohort study
GO25-GO27 (14:00~14:30) ÁÂÀå : ¹®Çý¼º(ÀÌÈ­ÀÇ´ë)
GO2514:00~14:10 ±è¼ö¿µ
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
Investigation of physician awareness regarding treatment options for cervical intraepithelial neoplasia 1 by using a survey questionnaire
GO2614:10~14:20 À̹æÇö
ÇѸ²ÀÇ´ë °­µ¿¼º½Éº´¿ø »êºÎÀΰú
Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study
GO2714:20~14:30 Á¤¿µ½Å
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
A sufficient number of relevant ethnic controls are needed for accurate assessment according to the ACMG standards and guidelines
GO28-GO30 (14:30~15:00) ÁÂÀå : ±èÈ«¹è(ÇѸ²ÀÇ´ë)
GO2814:30~14:40 ÃÖÀºÁö
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú
One institute experience of Robotic Single-Site Surgery, 300 Cases
GO2914:40~14:50 ¹ÚÁöÀº
°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Robotic infrarenal paraaortic lymphadenectomy with single-positioning approach using da Vinci Xi system: Initial experiences and comparison with dual-positioning approach using da Vinci S system
GO3014:50~15:00 ÃÖÂ÷Çö
¼º±Õ°üÀÇ´ë °­ºÏ»ï¼ºº´¿ø »êºÎÀΰú
Usefulness of hemostatic agents for minimizing ovarian damage during laparoscopic cystectomy for endometriosis